Literature DB >> 15256432

CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells.

Shannon A Shulby1, Nathan G Dolloff, Mark E Stearns, Olimpia Meucci, Alessandro Fatatis.   

Abstract

Chemokines and their receptors might be involved in the selection of specific organs by metastatic cancer cells. For instance, the CXCR4-SDF-1alpha pair regulates adhesion and migration of breast as well as prostate cancer cells to metastatic sites. In this study, we present the first evidence for the expression of CX3CR1--the specific receptor for the chemokine fractalkine--by human prostate cancer cells, whereas human bone marrow endothelial cells and differentiated osteoblasts express fractalkine. The adhesion of prostate cancer cells to human bone marrow endothelial cells in flow conditions is significantly reduced by a neutralizing antibody against fractalkine, and they migrate toward a medium conditioned by osteoblasts, which secrete the soluble form of the chemokine. Finally, fractalkine activates the PI3K/Akt survival pathway in human prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256432     DOI: 10.1158/0008-5472.CAN-03-3437

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  67 in total

1.  Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells.

Authors:  Mijung Kim; Lisa Rooper; Jia Xie; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Mol Cancer Res       Date:  2011-11-07       Impact factor: 5.852

Review 2.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

3.  Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion.

Authors:  Shailesh Singh; Rajesh Singh; Praveen K Sharma; Udai P Singh; Shesh N Rai; Leland W K Chung; Carlton R Cooper; Kristian R Novakovic; William E Grizzle; James W Lillard
Journal:  Cancer Lett       Date:  2009-04-17       Impact factor: 8.679

4.  Preliminary study correlating CX3CL1/CX3CR1 expression with gastric carcinoma and gastric carcinoma perineural invasion.

Authors:  Cheng-Yu Lv; Tao Zhou; Wei Chen; Xin-Dao Yin; Jian-Hong Yao; Yi-Fan Zhang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

5.  The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Authors:  Mike R Russell; Qingxin Liu; Hetian Lei; Andrius Kazlauskas; Alessandro Fatatis
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

6.  Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.

Authors:  Hina Mir; Neeraj Kapur; Rajesh Singh; Guru Sonpavde; James W Lillard; Shailesh Singh
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  Extravasation of leukocytes in comparison to tumor cells.

Authors:  Carina Strell; Frank Entschladen
Journal:  Cell Commun Signal       Date:  2008-12-04       Impact factor: 5.712

8.  Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.

Authors:  David L Blum; Tatsuki Koyama; Amosy E M'Koma; Juan M Iturregui; Magaly Martinez-Ferrer; Consolate Uwamariya; Joseph A Smith; Peter E Clark; Neil A Bhowmick
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

9.  Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.

Authors:  Shailesh Singh; Rajesh Singh; Udai P Singh; Shesh N Rai; Kristian R Novakovic; Leland W K Chung; Peter J Didier; William E Grizzle; James W Lillard
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

10.  Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.

Authors:  Ivan P Gorlov; Jinyoung Byun; Olga Y Gorlova; Ana M Aparicio; Eleni Efstathiou; Christopher J Logothetis
Journal:  BMC Med Genomics       Date:  2009-08-04       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.